94 related articles for article (PubMed ID: 8043438)
1. Assessment of therapeutic potential of interleukin 2 for myelodysplastic syndromes.
Ogata K; Yokose N; Ito T; An E; Tamura H; Dan K; Hamaguchi H; Sakamaki H; Onozawa Y; Nomura T
Br J Haematol; 1994 Mar; 86(3):562-7. PubMed ID: 8043438
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-2 therapy for myelodysplastic syndrome: does it work?
Ogata K; Yokose N; Nomura T
Leuk Lymphoma; 1995 May; 17(5-6):411-5. PubMed ID: 7549831
[TBL] [Abstract][Full Text] [Related]
3. Elevated plasma soluble interleukin 2 receptor level correlates with defective natural killer and CD8+ T-cells in myelodysplastic syndromes.
Yokose N; Ogata K; Ito T; An E; Tamura H; Dan K; Hamaguchi H; Sakamaki H; Onozawa Y; Nomura T
Leuk Res; 1994 Oct; 18(10):777-82. PubMed ID: 7934136
[TBL] [Abstract][Full Text] [Related]
4. Effects of interleukin-12 on natural killer cell cytotoxicity and the production of interferon-gamma and tumour necrosis factor-alpha in patients with myelodysplastic syndromes.
Ogata K; Tamura H; Yokose N; An E; Dan K; Hamaguchi H; Sakamaki H; Onozawa Y; Clark SC; Nomura T
Br J Haematol; 1995 May; 90(1):15-21. PubMed ID: 7786778
[TBL] [Abstract][Full Text] [Related]
5. Analysis of bone marrow and peripheral blood immunoregulatory lymphocytes in patients with myelodysplastic syndrome.
Iwase O; Aizawa S; Kuriyama Y; Yaguchi M; Nakano M; Toyama K
Ann Hematol; 1995 Dec; 71(6):293-9. PubMed ID: 8534761
[TBL] [Abstract][Full Text] [Related]
6. Lymphokine-activated killer cytotoxicity and lymphocyte subpopulations in patients with acute leukemia.
Parrado A; Casares S; Rodríguez-Fernández JM
Leuk Res; 1994 Nov; 18(11):815-22. PubMed ID: 7526078
[TBL] [Abstract][Full Text] [Related]
7. Clonal analysis of peripheral blood lymphocytes from three patients with advanced neuroblastoma receiving recombinant interleukin-2 and interferon alpha.
Prigione I; Facchetti P; Lanino E; Garaventa A; Pistoia V
Cancer Immunol Immunother; 1993 Jul; 37(1):40-6. PubMed ID: 8513451
[TBL] [Abstract][Full Text] [Related]
8. Effects of interleukin 2 on myelodysplastic syndromes.
Ogata K; Yokose N; Ito T; An E; Dan K; Nomura T
Leuk Res; 1993 Feb; 17(2):137-42. PubMed ID: 8429690
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the cytolytic activity of CD4+ and CD8+ tumor-infiltrating lymphocytes in human renal cell carcinoma.
Finke JH; Rayman P; Alexander J; Edinger M; Tubbs RR; Connelly R; Pontes E; Bukowski R
Cancer Res; 1990 Apr; 50(8):2363-70. PubMed ID: 2107973
[TBL] [Abstract][Full Text] [Related]
10. Enhanced human lymphokine-activated killer cell function after brief exposure to granulocyte-macrophage-colony stimulating factor.
Baxevanis CN; Dedoussis GV; Papadopoulos NG; Missitzis I; Beroukas C; Stathopoulos GP; Papamichail M
Cancer; 1995 Oct; 76(7):1253-60. PubMed ID: 8630906
[TBL] [Abstract][Full Text] [Related]
11. Changes in natural immunity during the course of HIV-1 infection.
Brenner BG; Gryllis C; Gornitsky M; Wainberg MA
Clin Exp Immunol; 1993 Aug; 93(2):142-8. PubMed ID: 7688673
[TBL] [Abstract][Full Text] [Related]
12. Binding of leukaemic blasts to various subpopulations of lymphokine-activated killer cells.
Palucka AK; Porwit A; Reizenstein P
Scand J Immunol; 1993 Feb; 37(2):179-85. PubMed ID: 7679523
[TBL] [Abstract][Full Text] [Related]
13. Human lymphokine-activated killer cells are cytotoxic against cells infected with Toxoplasma gondii.
Subauste CS; Dawson L; Remington JS
J Exp Med; 1992 Dec; 176(6):1511-9. PubMed ID: 1460415
[TBL] [Abstract][Full Text] [Related]
14. Adhesion molecules on MHC-nonrestricted lymphocytes: high density expression and role in oncolysis.
Savary CA; Lotzová E
Lymphokine Cytokine Res; 1992 Jun; 11(3):149-56. PubMed ID: 1391234
[TBL] [Abstract][Full Text] [Related]
15. [Study of subpopulations of lymphocytes in the bone marrow of patients with myelodysplastic syndromes].
Wiater E; Dwilewicz-Trojaczek J
Pol Arch Med Wewn; 2006 Mar; 115(3):210-8. PubMed ID: 18468426
[TBL] [Abstract][Full Text] [Related]
16. Lymphokine-activated killer function following autologous bone marrow transplantation for refractory hematological malignancies.
Higuchi CM; Thompson JA; Cox T; Lindgren CG; Buckner CD; Fefer A
Cancer Res; 1989 Oct; 49(20):5509-13. PubMed ID: 2477142
[TBL] [Abstract][Full Text] [Related]
17. Generation of human lymphokine-activated killer cells following an IL-2 pulse in elderly cancer patients.
Provinciali M; Di Stefano G; Stronati S; Fabris N
Cytokine; 1998 Feb; 10(2):132-9. PubMed ID: 9512903
[TBL] [Abstract][Full Text] [Related]
18. Lymphokine-activated killer-cell-mediated killing of WiDr colon carcinoma cells is inhibited by K562 erythroleukemia cells.
Dullens HF; Wind JC; Maas RA; Bernsen MR; Vulto IM; Rademakers LH; Den Otter W
Int Immunol; 1991 Oct; 3(10):959-64. PubMed ID: 1756146
[TBL] [Abstract][Full Text] [Related]
19. Long-term cultures of human peripheral blood lymphocytes with recombinant human interleukin-2 generate a population of virtually pure CD3+ CD16- CD56- large granular lymphocyte LAK cells.
Roussel E; Gerrard JM; Greenberg AH
Clin Exp Immunol; 1990 Nov; 82(2):416-21. PubMed ID: 1700746
[TBL] [Abstract][Full Text] [Related]
20. LAK-cell-mediated cytotoxicity against tumor cell targets used to monitor the stimulatory effect of interleukin-2: cytotoxicity, target recognition and phenotype of effector cells lysing the Daudi, T24 and K562 tumor cell lines.
Hermann GG; Zeuthen J; Claësson MH
Nat Immun; 1992; 11(1):7-16. PubMed ID: 1611282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
